AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma. (February 2019) - Iavarone, M.; Galmozzi, E.; De Silvestri, A.; Casadei-Gardini, A.; Piscaglia, F.; Marisi, G.; Facchetti, F.; Faloppi, L.; Ielasi, L.; Tovoli, F.; Cimino, A.; Scartozzi, M.; et al.